-
公开(公告)号：US20090280085A1
公开(公告)日：2009-11-12
申请号：US12475490
申请日：2009-05-30
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
Abstract translation: 为干扰素类似物提供了组合物，试剂盒和方法，以促进一般健康或治疗疾病。 人类干扰素类似物通过干扰素与人血清白蛋白的融合来制备。 生物测定显示具有相同抗细胞病毒侵袭能力的干扰素类似物在体内比干扰素具有3-10倍的作用功能。 这些新型长效干扰素类似物可用于治疗病毒感染患者，如SARS病毒，HIV，HCV，HBV或HAV，以及癌症疾病如白血病和恶性黑色素瘤。 与干扰素相比，它们的保质期还有3-5倍。
-
公开(公告)号：US07572437B2
公开(公告)日：2009-08-11
申请号：US10851666
申请日：2004-05-24
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
-
公开(公告)号：US20090053173A1
公开(公告)日：2009-02-26
申请号：US10851666
申请日：2004-05-24
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
Abstract translation: 为干扰素类似物提供了组合物，试剂盒和方法，以促进一般健康或治疗疾病。 人类干扰素类似物通过干扰素与人血清白蛋白的融合来制备。 生物测定显示具有相同抗细胞病毒侵袭能力的干扰素类似物在体内比干扰素具有3-10倍的作用功能。 这些新型长效干扰素类似物可用于治疗病毒感染患者，如SARS病毒，HIV，HCV，HBV或HAV，以及癌症疾病如白血病和恶性黑色素瘤。 与干扰素相比，它们的保质期还有3-5倍。
-
44.发明授权Recombinant human albumin-erythropoietin fusion proteins with long-lasting biological effects 有权重组人白蛋白促红细胞生成素融合蛋白具有持久的生物学作用公开(公告)号：US07442371B2
公开(公告)日：2008-10-28
申请号：US11825686
申请日：2007-07-08
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。
-
公开(公告)号：US07367586B2
公开(公告)日：2008-05-06
申请号：US10908367
申请日：2005-05-09
Applicant: Weigang Chen , Yan Fu , Baohua Xiao , Marwan Ahmad El-Bkaily
Inventor： Weigang Chen , Yan Fu , Baohua Xiao , Marwan Ahmad El-Bkaily
IPC: B60R21/18
CPC classification number: B60R21/233 , B60R21/203 , B60R21/2338 , B60R2021/23382
Abstract: An airbag restraint for an automotive vehicle includes generally circular front and rear panels, and an inflator attached to the rear panel and acting through an inflator aperture formed in the rear panel. At least one internally tethered section extends laterally along a chord of the front panel at a position at or near the projected location of the inflator. The internally tethered section is defined and shaped by more than one laterally extending tether extending between the front and rear panels of the airbag.
Abstract translation: 用于机动车辆的安全气囊限制装置包括大致圆形的前后面板，以及附接到后面板并通过形成在后面板中的充气机孔作用的充气机。 至少一个内部连接部分沿着充气机的突出位置处或附近的位置沿着前面板的弦横向延伸。 内部连接部分由在气囊的前面板和后面板之间延伸的多于一个横向延伸的系绳限定和成形。
-
Patent Agency Ranking
公开(公告)号：US20060051859A1
公开(公告)日：2006-03-09
申请号：US10936447
申请日：2004-09-09
CPC classification number: C07K14/555 , C07K2319/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
-
47.发明授权公开(公告)号：US06709863B2
公开(公告)日：2004-03-23
申请号：US09897776
申请日：2001-06-29
Applicant: Patrick S. Schnable , Feng Liu , Yan Fu
Inventor： Patrick S. Schnable , Feng Liu , Yan Fu
IPC: C12N510
CPC classification number: C12N15/1086 , C07K2319/21 , C12N15/1065 , C12N15/62
Abstract: Compositions and methods for identifying nucleotide fragments that contain an open reading frame are provided. Compositions comprise a nucleotide sequence that encodes, in each of the three possible reading frames, an ATG start codon and a histidine tag, and vectors comprising such a nucleotide sequence. The vectors may be provided with cloning sites for insertion of nucleotide sequences of interest 5′ or 3′ to the 3-frame His-tag DNA sequence. Vectors also are provided with cloning sites for inserting nucleotide sequences of interest 3′ of the ATG start codon and 5′ of the 3-frame His-tag DNA sequence.
Abstract translation: 提供了用于鉴定包含开放阅读框架的核苷酸片段的组合物和方法。 组合物包含在三个可能的阅读框中的每一个中编码ATG起始密码子和组氨酸标签的核苷酸序列，以及包含这种核苷酸序列的载体。 可以向载体提供用于将感兴趣的5'或3'的核苷酸序列插入3框架His标签DNA序列的克隆位点。 载体还提供有用于插入ATG起始密码子的3'和3框His标签DNA序列的5'的感兴趣的核苷酸序列的克隆位点。
-
48.发明授权公开(公告)号：US06428961B1
公开(公告)日：2002-08-06
申请号：US09732990
申请日：2000-12-08
Applicant: Patrick S. Schnable , Feng Liu , Yan Fu
Inventor： Patrick S. Schnable , Feng Liu , Yan Fu
IPC: C12N514
CPC classification number: C12N15/1065 , C07K2319/21 , C12N15/62
Abstract: Compositions and methods for identifying nucleotide fragments that contain an open reading frame are provided. Compositions comprise a nucleotide sequence that encodes histidine tags in each of the three possible reading frames and vectors comprising such a nucleotide sequence. The vectors may be provided with cloning sites for insertion of nucleotide sequences 5′ or 3′ to the 3-frame His-tag DNA sequence.
Abstract translation: 提供了用于鉴定包含开放阅读框架的核苷酸片段的组合物和方法。 组合物包含在三个可能的阅读框中的每一个中编码组氨酸标签的核苷酸序列和包含这种核苷酸序列的载体。 可以向载体提供用于将核苷酸序列5'或3'插入3框架His标签DNA序列的克隆位点。
-
公开(公告)号：US5624489A
公开(公告)日：1997-04-29
申请号：US377109
申请日：1995-01-23
Applicant: Yan Fu , Jian Ding , James J. Beaudoin
Inventor： Yan Fu , Jian Ding , James J. Beaudoin
CPC classification number: C04B28/06 , Y02W30/92 , Y02W30/94 , Y10S106/01
Abstract: Additives for high alumina cement compositions are proposed. The additives are effective to reduce or prevent the deleterious conversion of hexagonal calcium aluminate hydrates to cubic hydrogarnet in the high alumina cement compositions. The additives comprise 80-99 wt. % of a siliceous pozzolan and 1-20 wt. % of an inorganic sodium or potassium salt.
Abstract translation: 提出了高铝水泥组合物的添加剂。 这些添加剂有效地减少或防止了高铝水泥组合物中六角晶铝酸钙水合物的有害转化为立方氢化球。 添加剂包含80-99wt。 ％的硅质火山灰和1-20重量％ ％的无机钠盐或钾盐。
-
50.发明授权Method of use and preparation of HSA fusion protein composition for skincare 有权HSA融合蛋白组合物用于护肤品的使用和制备方法公开(公告)号：US09114094B2
公开(公告)日：2015-08-25
申请号：US14064701
申请日：2013-10-28
IPC: A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , C12N15/00 , C12N15/09 , C12N15/11 , C12N15/12 , C12N15/62 , C12N15/63 , C12N15/81 , A61K8/64 , A61K9/00 , A61K9/06 , A61K9/107 , A61K38/38 , A61Q19/02 , A61Q19/08 , C07K14/475 , A61K38/19 , A61K38/20 , A61K38/21 , A61K38/30 , A61K36/064 , A61K8/99 , A61Q5/12 , A61Q11/00 , A61Q19/00
CPC classification number: A61K8/64 , A61K8/99 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K36/064 , A61K38/1808 , A61K38/1816 , A61K38/1858 , A61K38/193 , A61K38/20 , A61K38/217 , A61K38/30 , A61K38/38 , A61Q5/12 , A61Q11/00 , A61Q19/00 , A61Q19/02 , A61Q19/08 , C07K14/475 , C07K2319/00 , A61K2300/00
Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
Abstract translation: 本发明提供了一种重组融合蛋白，其能刺激皮肤和表皮细胞的复原和再激活，以改善皮肤外观，使皱纹和雀斑平滑，以及美白皮肤。 特别地，本发明提供各种类型的用于改善皮肤的产品，其含有人血清白蛋白（HSA）与细胞因子肽（EGF，FGF，KGF，HGH，HGF，PDGF，GCSF，干扰素，IL-11或 IGF）通过基因工程技术。 融合蛋白可以独立使用或与酵母发酵产物组合使用，或与各种乳化剂，增稠剂，保湿剂，防腐剂，酵母和发酵剂组合使用。
-
-
-
-
-
-
-
-
-
Search Results
65
records
(took 0.03 seconds)
